Avara buys the largest sterile manufacturing facility in Canada

| By | CDMO, Contract Manufacturing

Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), announced that it has agreed to acquire the largest sterile manufacturing facility for injectable medicines in Canada from a leading global pharmaceutical company.

The proposed acquisition of Novartis Technical Operations’ sterile manufacturing facility and the adjacent Sandoz Development Center located on the Sandoz Canada campus in Boucherville, Quebec, is expected to be finalized in the next few months, following the completion of a number of closing conditions including receipt of anti-trust approvals. It follows Avara’s acquisition of another sterile facility in the past year, one from Pfizer Inc. in Liscate, Italy, and one solid dose manufacturing facility from GlaxoSmithKline in Aiken, South Carolina. It will bring the number of manufacturing and development sites operated by Avara worldwide to ten: two in Canada; three in the United States, including corporate headquarters; one in Puerto Rico; one in the UK; one in Ireland; one in Italy; and one in France.

The Boucherville site is the biggest injectables production facility in Canada and provides a number of strategic and lifesaving medicines to the Canadian healthcare system, mostly hospitals. As part of the asset purchase agreement, the parties have committed to sign a long-term supply contract to guarantee continuous supply of products manufactured in Boucherville. No impact on jobs is anticipated at the moment and Avara intends to invest in the site and pursue business development opportunities to optimize the plant’s utilization and expand its customer base.

Avara Pharmaceutical Services, based in Norwalk, Connecticut (USA) is an international pharmaceutical services company that delivers world-class contract manufacturing and technical services to the pharmaceutical industry.

SOURCE: prnewswire.com
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.